Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Conditions:   BRAF V600E Negative;   KRAS Gene Mutation Negative;   Locally Advanced Unresectable Colorectal Adenocarcinoma;   Metastatic Colorectal Adenocarcinoma;   NRAS Gene Mutation Negative;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage  IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8 Interventions:   Biological: Cetuximab;   Drug: Irinotecan;   Biological: Panitumumab;   Drug: Regorafenib Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials